ConductScience.org, home
TEAD4: TEA domain transcription factor 4
API referenceFor AI assistants

Gene · 7004

Papers1,824

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

41 to 60 of 1,824

Download this page as JSON
TitleJournalYearPMIDFound bySource
A Cross-Species Hydroquinone Model Replicates Smoking-Related Corneal Endothelial Oxidative Injury and Enables Therapeutic Screening of FGF10.Invest Ophthalmol Vis Sci202641789845PubTator, text miningPubMed
Challenges and advances in drug resistance and tolerance in cancer.J Exp Clin Cancer Res202641776655PubTator, text miningPubMed
The Hippo pathway in clear cell renal cell carcinoma (ccRCC): a nexus with the VHL disruption?Transl Oncol202641764979PubTator, text miningPubMed
TEAD4 Identified as a Potential Biomarker for Gastric Cancer Via Genes Associated with Liquid-Liquid Phase Separation.Curr Protein Pept Sci202641764605PubTator, text miningPubMed
MCM10, a novel YAP1/TEAD4 target, drives gastric cancer progression by bridging DNA replication to stemness acquisition.Mol Cancer202641761192PubTator, text miningPubMed
Comprehensive analysis of the deleterious nonsynonymous, non-coding SNPs and cancer variants of human aldo-keto reductase type 1 (AKR1C1) protein and their probable association with disease risk and progression: a computational study.
Biochem Biophys Rep202641756011PubTator, text miningPubMed
Telomeric Ends and Telomerase-Canonical and Non-Canonical Roles in Breast Cancer Tumorigenesis and Therapy Resistance.Biomedicines202641751213PubTator, text miningPubMed
Subtype-Dependent Expression Patterns of Core Hippo Pathway Components in Thymic Epithelial Tumors (TETs): An RT-qPCR Study.Biomedicines202641751203PubTator, text miningPubMed
Cardiac drug potential: exploring individual and combined cardiac drugs to promote differentiation of adipose-derived stem cells into cardiomyocytes.Mol Biol Rep202641746444PubTator, text miningPubMed
GelMA-Based Nanocomposites for Bone Defect Regeneration: Design, Performance, and Clinical Translation Potential.Int J Nanomedicine202641737038PubTator, text miningPubMed
From hPSCs to MSCs: differentiation strategies, pathways, and the emergence of common regulatory networks.Cell Mol Biol Lett202641735837PubTator, text miningPubMed
PFKP binding AMOTL1 promotes tumor aerobic glycolysis and epithelial-mesenchymal transition by modulating Hippo pathway in head and neck cancer.J Transl Int Med202641727965PubTator, text miningPubMed
Beyond the membrane: Internalization and compartmentalization of insulin‑like growth factor 1 receptor signaling in cancer pathogenesis and treatment (Review).Int J Oncol202641716020PubTator, text miningPubMed
Integrative machine learning identifies a TEAD4-driven endothelial program shaping drug sensitivity and microvascular invasion in HCC.J Transl Med202641664193PubTator, text miningPubMed
Molecular biology of pituitary neuroendocrine tumors.J Neurooncol202641639477PubTator, text miningPubMed
Characterization, organoid formation and differentiation potential of the novel term trophoblast cell line TB/SVTERT350.Placenta202641637934PubTator, text miningPubMed
VGLL4 modulates Paneth cells and sustains intestinal homeostasis.EMBO Rep202641629625PubTator, text miningPubMed
Design and Validation of a Predictive Model for Hepatocellular Carcinoma Based on Genes With Differential Expression Driven by DNA Methylation.Int J Genomics202641607685PubTator, text miningPubMed
Positive feedback regulation between USP8 and Hippo/YAP axis drives triple-negative breast cancer progression.Cell Death Dis202641565619PubTator, text miningPubMed
Gene regulatory network transitions reveal the central transcription factors in lung adenocarcinoma progression.NPJ Syst Biol Appl202641559111PubTator, text miningPubMed

gene-search-2026-11-11-0.2.0

Previous pageNext page

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/genes/v1/7004/papers?page=3

API referenceFor AI assistants